Investigational drug · Phase 3
Cadonilimab
Also called: AK104
Not approved by FDA. In 31 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
31
27 still active
All registered trials
174
Any phase or sponsor naming "Cadonilimab"
First trial start
2021
Aug 23, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
- Akeso28
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Cadonilimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Cervical Cancer
- Advanced Non-small-cell Lung Cancer
- Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- Pancreatic Cancer
- Metastatic Pancreatic Ductal Adenocarcinoma
- Renal Cell Carcinoma, Clear Cell
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Approved drugs for the same conditions: Small cell lung cancer · Pancreatic cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Cervical cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Cadonilimab" as an intervention, largest first.
AkesoIndustry
NCT07700979 · 900 participants (planned) · Start Sep 24, 2026 · Primary completion Aug 18, 2029
Drug: Cadonilimab; CAPOX regimen and 2 more · For: Gastric / Gastroesophageal Junction Adenocarcinoma
Sites: Phoenix, Arizona; Los Angeles, California; Denver, Colorado · 25 sites in all
- A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ AdenocarcinomaPivotal-lookingRecruiting
AkesoIndustry
NCT07023315 · 760 participants (planned) · Start Aug 14, 2025 · Primary completion Jul 2029
Drug: Cadonilimab; SOX chemotherapy and 1 more · For: Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Sites: Beijing, China; Fuzhou, China; Shijiazhuang, China · 6 sites in all
- A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical CancerNot yet recruiting
Gang Chen (101199)Academic, hospital or other
NCT06155422 · 670 participants (planned) · Start Nov 30, 2023 · Primary completion Nov 30, 2026
Drug: Cadonilimab · For: Recurrent or Metastatic Cervical Cancer
- Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaPivotal-lookingRecruiting
Zuoyi JiaoAcademic, hospital or other
NCT06949033 · 668 participants (planned) · Start May 15, 2025 · Primary completion Dec 31, 2028
Drug: Neoadjuvant cadonilimab combined with perioperative SOX; Neoadjuvant placebo plus perioperative SOX · For: Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]); Neoadjuvant Therapy; Adjuvant Chemotherapy and 3 more
Sites: Lanzhou, China · 4 sites in all
- A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCPivotal-lookingRecruiting
AkesoIndustry
NCT06617416 · 560 participants (planned) · Start Nov 12, 2024 · Primary completion Oct 28, 2026
Drug: Cadonilimab (AK104); Sugemalimab · For: NSCLC (Non-small Cell Lung Cancer)
Sites: Jinan, China
- A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaPivotal-lookingRecruiting
AkesoIndustry
NCT06341335 · 506 participants (planned) · Start Jun 19, 2024 · Primary completion Nov 2026
Drug: cadonilimab; pulocimab and 2 more · For: Gastric and Gastroesophageal Junction Adenocarcinoma
Sites: Beijing, China
- Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)Pivotal-lookingActive, not recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT05587374 · 490 participants (planned) · Start Aug 1, 2023 · Primary completion Aug 1, 2027
Drug: Cadonilimab; Gemcitabine and 1 more · For: Nasopharyngeal Carcinoma; Nasopharyngeal Cancer
Sites: Bengbu, China; Hefei, China; Beijing, China · 18 sites in all
- A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular CarcinomaPivotal-lookingRecruiting
AkesoIndustry
NCT06371157 · 469 participants (planned) · Start Aug 2, 2024 · Primary completion Oct 25, 2025
Drug: AK104; Lenvatinib · For: Hepatocellular Carcinoma
Sites: Zhengzhou, China; Changsha, China; Nanjing, China · 4 sites in all
- Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon CancerPivotal-lookingRecruiting
AkesoIndustry
NCT07412613 · 386 participants (planned) · Start Apr 15, 2026 · Primary completion Jun 15, 2030
Drug: Cadonilimab (AK104); Oxaliplatin and 3 more · For: Resectable Colon Cancer; MSI-H/dMMR Colorectal Cancer
Sites: Guangzhou, China
- IC Plus Low-dose Radiation Plus Cadonilimab in LANPCPivotal-lookingRecruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT05941741 · 380 participants (planned) · Start Jan 10, 2024 · Primary completion Dec 2027
Drug: Chemotherapy; Immune checkpoint inhibitor · For: Nasopharyngeal Carcinoma; Immune Checkpoint Inhibitor; Radiotherapy and 1 more
Sites: Guangzhou, China; Nanning, China; Nanchang, China
Newest research
PubMed records naming it or its code names, newest first.
- Ivonescimab combined with chemotherapy for the treatment of metastatic cervical cancer: A case report and literature review.
Xu M, Qiu S, Zhou J, et al. · Hum Vaccin Immunother 2026
- PD-1/PD-L1 inhibitors plus chemotherapy in cervical cancer: A systematic review and meta-analysis.
Wijayanto FPS, Simanjuntak AMT, Sirait PCNB, et al. · Turk J Obstet Gynecol 2026
- Pathological Complete Response in Stage IV Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer With Synchronous Liver Metastases After Conversion Therapy With SOX Plus Cadonilimab and Disitamab Vedotin.
Shi X, Wang WJ, He KJ, et al. · Gastroenterology Res 2026
- PF chemotherapy combined with a PD-1/CTLA-4 bispecific antibody as first-line treatment in patients with recurrent/metastatic head and neck squamous cell carcinoma: a prospective, single-arm, phase II clinical study.
Liao W, Li Q, Deng Y, et al. · Front Oncol 2026
- Combination therapies for the treatment of locally advanced and advanced cervical cancer.
Duenas-Gonzalez A, Pastrana-Peralta P, Romo-Pérez A, et al. · Expert Opin Pharmacother 2026
- Cadonilimab plus gemcitabine and cisplatin as first-line treatment for unresectable locally advanced or metastatic biliary tract malignancies: the phase II bicureX clinical trial.
Ma J, Wang T, Zheng Y, et al. · Nat Commun 2026
Also in development for Hepatocellular Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.